Overview

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Efficacy of BI 1356 compared to placebo in patients for whom metformin therapy is inappropriate (intolerability, contraindication). The second part of the study looks at the safety of BI 1356 in this patient population with longer term treatment in comparison to a sulfonylurea drug (glimepiride)

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Glimepiride
Linagliptin
Metformin